See more : Bank of Chengdu Co., Ltd. (601838.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Theratechnologies Inc. (THTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theratechnologies Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Reato Group AB (publ) (DOME.ST) Income Statement Analysis – Financial Results
- Kennede Electronics MFG. Co., Ltd. (002723.SZ) Income Statement Analysis – Financial Results
- Scryb Inc. (SCYB.CN) Income Statement Analysis – Financial Results
- Carlyle Commodities Corp. (DLRYF) Income Statement Analysis – Financial Results
- RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (OPP-PA) Income Statement Analysis – Financial Results
Theratechnologies Inc. (THTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.theratech.com
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.76M | 80.06M | 69.82M | 66.05M | 63.22M | 44.05M | 33.23M | 27.60M | 22.55M | 5.90M | 7.13M | 13.66M |
| Cost of Revenue | 19.64M | 26.28M | 23.26M | 26.90M | 26.08M | 14.68M | 17.15M | 10.14M | 6.70M | 7.07M | 10.46M | 11.47M |
| Gross Profit | 62.13M | 53.78M | 46.56M | 39.15M | 37.14M | 29.38M | 16.07M | 17.47M | 15.85M | -1.17M | -3.33M | 2.18M |
| Gross Profit Ratio | 75.99% | 67.17% | 66.69% | 59.27% | 58.75% | 66.68% | 48.37% | 63.28% | 70.29% | -19.90% | -46.72% | 15.99% |
| Research & Development | 30.37M | 36.94M | 28.27M | 18.02M | 10.84M | 7.77M | 9.19M | 5.65M | 4.11M | 4.95M | 7.09M | 7.08M |
| General & Administrative | 15.62M | 17.36M | 14.62M | 12.23M | 8.33M | 5.83M | 4.51M | 3.57M | 2.99M | 4.00M | 3.55M | 5.50M |
| Selling & Marketing | 26.77M | 39.39M | 28.91M | 26.86M | 26.48M | 21.69M | 20.17M | 10.86M | 9.66M | 6.10M | 236.05K | 857.67K |
| SG&A | 42.39M | 56.75M | 43.53M | 39.09M | 34.81M | 25.02M | 24.67M | 14.54M | 12.74M | 10.10M | 3.84M | 6.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 850.00K | 22.07M |
| Operating Expenses | 72.76M | 93.69M | 71.80M | 57.11M | 45.65M | 32.79M | -30.64M | -16.76M | -14.28M | -8.21M | -901.69K | -16.97M |
| Cost & Expenses | 92.39M | 119.97M | 95.06M | 84.01M | 71.73M | 47.47M | -13.48M | -6.63M | -7.58M | -1.14M | 9.56M | -5.50M |
| Interest Income | 0.00 | 316.00K | 195.00K | 299.00K | 1.10M | 285.00K | 261.99K | 77.44K | 30.76K | 173.52K | 429.60K | 762.04K |
| Interest Expense | 10.55M | 6.50M | 5.66M | 5.36M | 4.99M | 2.53M | 1.07M | 1.44M | 1.87M | 1.05M | 12.25K | 23.12K |
| Depreciation & Amortization | 3.30M | 12.03M | 8.58M | 8.84M | 7.50M | 4.14M | 1.55M | 1.57M | 1.44M | 1.00M | 114.25K | 567.75K |
| EBITDA | -10.31M | -27.87M | -17.16M | -9.18M | 28.01K | 731.32K | -11.68M | 3.79M | 4.55M | -6.68M | -7.06M | -3.60M |
| EBITDA Ratio | -12.61% | -33.92% | -23.38% | -13.89% | 0.06% | 1.66% | -21.24% | 16.31% | 20.17% | -113.15% | -98.94% | -26.39% |
| Operating Income | -10.63M | -39.91M | -25.24M | -17.96M | -8.51M | -3.41M | -8.60M | 2.93M | 3.11M | -7.68M | -7.17M | -4.17M |
| Operating Income Ratio | -13.00% | -49.85% | -36.14% | -27.19% | -13.47% | -7.75% | -25.89% | 10.62% | 13.79% | -130.11% | -100.54% | -30.54% |
| Total Other Income/Expenses | -12.91M | -6.89M | -6.43M | -4.69M | -3.98M | -2.56M | -5.72M | -2.15M | -1.50M | -1.53M | 3.37M | -9.86M |
| Income Before Tax | -23.54M | -46.79M | -31.66M | -22.65M | -12.50M | -5.77M | -14.30M | 781.10K | 1.61M | -9.21M | -3.80M | -14.03M |
| Income Before Tax Ratio | -28.79% | -58.45% | -45.35% | -34.29% | -19.77% | -13.11% | -43.04% | 2.83% | 7.12% | -156.12% | -53.34% | -102.71% |
| Income Tax Expense | 421.00K | 443.00K | 63.00K | 16.00K | 4.99M | -1.25M | -2.17K | 475.81K | 426.91K | 27.17K | 24.55K | 5.03K |
| Net Income | -23.96M | -47.24M | -31.73M | -22.67M | -12.50M | -4.52M | -14.30M | 305.29K | 1.18M | -9.24M | -3.83M | -14.03M |
| Net Income Ratio | -29.30% | -59.00% | -45.44% | -34.32% | -19.77% | -10.27% | -43.04% | 1.11% | 5.23% | -156.58% | -53.69% | -102.75% |
| EPS | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.06 | -0.61 | -0.25 | -0.93 |
| EPS Diluted | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.07 | -0.61 | -0.25 | -0.92 |
| Weighted Avg Shares Out | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.45M | 19.64M | 15.25M | 15.25M | 15.15M |
| Weighted Avg Shares Out (Dil) | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.65M | 15.79M | 15.25M | 15.25M | 15.25M |
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
MONTREAL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has...
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received correspondence from the U.S. Food and Drug Administration (FDA)...
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
MONTREAL, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has filed a supplemental Biologics License...
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
MONTREAL , Dec. 21, 2023 /PRNewswire/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf...
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
MONTREAL, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug Administration (FDA)...
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide...
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering...
Why Is Theratechnologies (THTX) Stock Down 22% Today?
Theratechnologies (NASDAQ: THTX ) stock is dropping on Thursday after the biopharmaceutical company announced a proposed public share offering. Theratechnologies is selling 12.5 million shares of THTX stock at a price of $1 per share.
Source: https://incomestatements.info
Category: Stock Reports